Literature DB >> 17952614

Extravasation and homing mechanisms in multiple myeloma.

Isabelle Vande Broek1, Karin Vanderkerken, Benjamin Van Camp, Ivan Van Riet.   

Abstract

Multiple myeloma (MM) is a malignant B-cell disorder characterized by a monoclonal expansion of plasma cells (PC) in the bone marrow (BM). During the main course of disease evolution, MM cells depend on the BM microenvironment for their growth and survival. Reciprocal interactions between MM cells and the BM mediate not only MM cell growth, but also protect them against apoptosis and cause bone disease and angiogenesis. A striking feature of MM represents the predominant localization and retention of MM cells in the BM. Although BM PC indeed represent the main neoplastic cell type, small numbers of MM cells can also be detected in the peripheral blood circulation. It can be assumed that these circulating cells represent the tumour-spreading component of the disease. This implicates that MM cells have the capacity to (re)circulate, to extravasate and to migrate to the BM (homing). In analogy to the migration and homing of normal leucocytes, the BM homing of MM cells is mediated by a multistep process of extravasation with adhesion to the endothelium, invasion of the subendothelial basement membrane, followed by further migration within the stroma, mediated by chemotactic factors. At the end stage of disease, MM cells are thought to develop autocrine growth supporting loops that enable them to survive and proliferate in the absence of the BM microenvironment and to become stroma-independent. In this stage, the number of circulating cells increases and growth at extramedullary sites can occur, associated with alteration in adhesion molecule and chemokine receptor expression. This review summarizes the recent progress in the study of the extravasation and homing mechanisms of MM cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952614     DOI: 10.1007/s10585-007-9108-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  95 in total

1.  Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

Authors:  D Gupta; S P Treon; Y Shima; T Hideshima; K Podar; Y T Tai; B Lin; S Lentzsch; F E Davies; D Chauhan; R L Schlossman; P Richardson; P Ralph; L Wu; F Payvandi; G Muller; D I Stirling; K C Anderson
Journal:  Leukemia       Date:  2001-12       Impact factor: 11.528

2.  The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; Klaus Podar; Masaharu Akiyama; Deepak Gupta; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2002-05       Impact factor: 6.261

3.  Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential.

Authors:  Tali Tohami; Liat Drucker; Hava Shapiro; Judith Radnay; Michael Lishner
Journal:  FASEB J       Date:  2007-01-08       Impact factor: 5.191

4.  In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.

Authors:  K Asosingh; H De Raeve; P Croucher; E Goes; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Exp Hematol       Date:  2001-01       Impact factor: 3.084

5.  CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.

Authors:  Yu-Tzu Tai; Klaus Podar; Nicholas Mitsiades; Boris Lin; Constantine Mitsiades; Deepak Gupta; Masaharu Akiyama; Laurence Catley; Teru Hideshima; Nikhil C Munshi; Steven P Treon; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

6.  Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

Authors:  F Di Raimondo; M P Azzaro; G Palumbo; S Bagnato; G Giustolisi; P Floridia; G Sortino; R Giustolisi
Journal:  Haematologica       Date:  2000-08       Impact factor: 9.941

7.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

8.  Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Authors:  Eline Menu; Evy De Leenheer; Hendrik De Raeve; Les Coulton; Takeshi Imanishi; Kazuyuki Miyashita; Els Van Valckenborgh; Ivan Van Riet; Ben Van Camp; Richard Horuk; Peter Croucher; Karin Vanderkerken
Journal:  Clin Exp Metastasis       Date:  2006-11-03       Impact factor: 5.150

9.  A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.

Authors:  Angelo Vacca; Roberto Ria; Domenico Ribatti; Fabrizio Semeraro; Valentin Djonov; Francesco Di Raimondo; Franco Dammacco
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

10.  Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells.

Authors:  B K Arendt; A Velazquez-Dones; R C Tschumper; K G Howell; S M Ansell; T E Witzig; D F Jelinek
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528

View more
  42 in total

1.  Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness.

Authors:  Liat Nadav; Vyacheslav Kalchenko; Meir Max Barak; Elizabeth Naparstek; Benjamin Geiger; Ben-Zion Katz
Journal:  Exp Hematol       Date:  2008-08-09       Impact factor: 3.084

2.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

3.  Shear flow-induced formation of tubular cell protrusions in multiple myeloma cells.

Authors:  Ziv Porat; Itamar Yaron; Ben-Zion Katz; Zvi Kam; Benjamin Geiger
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

Review 4.  Early onset multiple myeloma in a patient with systemic lupus erythematosus: a case report and literature review.

Authors:  Jin Woo Choi; Seung Woo Han; Ki Tae Kwon; Gun Woo Kim
Journal:  Clin Rheumatol       Date:  2010-03-07       Impact factor: 2.980

5.  Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.

Authors:  Jerome T Higgs; Joo Hyoung Lee; Hong Wang; Vishnu C Ramani; Diptiman Chanda; Cherlene Y Hardy; Ralph D Sanderson; Selvarangan Ponnazhagan
Journal:  Blood Adv       Date:  2017-11-21

6.  PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Authors:  Mulu Z Tesfay; Amber C Kirk; Elizabeth M Hadac; Guy E Griesmann; Mark J Federspiel; Glen N Barber; Stephen M Henry; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

Review 7.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

8.  Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Authors:  Valentina Marchica; Fabrizio Accardi; Paola Storti; Cristina Mancini; Eugenia Martella; Benedetta Dalla Palma; Marina Bolzoni; Katia Todoerti; Magda Marcatti; Chiara Schifano; Sabrina Bonomini; Gabriella Sammarelli; Antonino Neri; Maurilio Ponzoni; Franco Aversa; Nicola Giuliani
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

9.  High-content adhesion assay to address limited cell samples.

Authors:  Jay W Warrick; Edmond W K Young; Eric G Schmuck; Kurt W Saupe; David J Beebe
Journal:  Integr Biol (Camb)       Date:  2013-02-21       Impact factor: 2.192

Review 10.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.